New hope for anemia patients in groundbreaking bone marrow trial
NCT ID NCT05399732
Summary
This study tested whether adding a new drug called luspatercept to standard treatment could better improve blood cell counts in adults with a specific, non-severe form of aplastic anemia. Aplastic anemia is a rare condition where the bone marrow fails to make enough blood cells. Researchers compared the combination therapy against the standard treatment alone in 58 newly diagnosed patients to see which was more effective and safe over six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking union medical college hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.